Skip to main content

Adaptive Biotechnologies Corp

corporate_fare Company Profile

Adaptive Biotechnologies Corp

ADPT·NASDAQ·Life Sciences·CIK 0001478320

Our company advances immune medicine by using proprietary technologies to decode a patient's adaptive immune system. This involves reading the genetic code of the immune system to understand how it detects and treats disease. These insights are stored in a clinical immunomics database, supported by computational biology and machine learning, to develop and commercialize tailored clinical products and services. In 2024, the company reorganized into two main businesses: the "MRD business" and "Immune Medicine" (IM business). The MRD business focuses on the clinical assessment of minimal residual disease (MRD) in lymphoid malignancies. This business utilizes a highly sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. It includes the clonoSEQ clinical diagnostic test for clinicians and the clonoSEQ assay for biopharmaceutical partners to support drug development ("MRD Pharma"). The total addressable market for the MRD business is approximately $6.2 billion, with approximately $5.3 billion from clinical testing. clonoSEQ is the first FDA-authorized test for detecting and monitoring MRD in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). It is also available as a CLIA-validated laboratory developed test (LDT) for other lymphoid cancers, including diffuse large B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). The IM business focuses on creating applications and products that connect adaptive immune responses to disease.

Adaptive Biotechnologies Corp (NASDAQ:ADPT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for ADPT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for ADPT spans 10-Q, 4, 8-K, 144.

Recent high-impact activity:

  • Adaptive 10-Q: Q3 Revenue $83.9M, Net Income $2.9M, Cash $400.2M
  • Adaptive Biotechnologies Beats Q3 Revenue Estimates With $83.9M, Swings to Profit
  • NCCN Guidelines Now Specifically Name clonoSEQ, Prefer 10^-6 MRD Sensitivity in Myeloma
  • CEO Chad Robins Sells $14.9M in Stock After Exercising Options
  • Adaptive Biotechnologies Beats Q2 Revenue, Lifts MRD Guidance, and Plans Business Separation

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$276.98M
Net Income
-$59.5M
Diluted EPS
-$0.39
Op. Cash Flow
-$45.99M
Free Cash Flow
-$48.95M
Gross Profit
$205.62M
Operating Income
-$57.12M
Cash & Equivalents
$70.5M
Total Debt
$131.21M
Debt / Equity
0.60×
Net Margin
-21.5%
Shares Outstanding
153.78M sh
Source: 10-K · filed 2026-02-26 · accession 0001193125-26-076902

Short Interest & Short Volume

6.07 days to cover

FINRA reported short interest of 11,478,831 shares in ADPT as of the October 30, 2026 settlement, a 4.3% decrease from the prior period — about 6.1 days to cover at its recent average daily volume. On November 20, 2026, 40.6% of ADPT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)11,478,831 shares as of October 30, 2026
Change vs prior period▼ 4.3%
Days to cover6.07 at avg daily volume of 1,889,527
Daily short volume (FINRA facilities)40.6% of 551,272 shares on November 20, 2026
5-day average short volume47.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for ADPT, detected from its recent SEC filings · based on capital-structure filings through 2026-06-22.

Convertible Notes Issued · OrbiMed Debt Repaid

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$27.89 -0.14% today
52-week range · as of 2026-11-04 $12 – $30.74
Market cap
$4.52B
Volume
2.5M (1.1× avg)
3-mo avg 2.2M
Live data · 2026-11-21 21:15 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ADPT - Latest Insights

ADPT
Nov 04, 2026, 4:30 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $28.48
Real-time Price: $27.89 info
Change: -$0.5879 (-2%) info
Market Cap: $4.521B info
ADPT
Nov 04, 2026, 4:06 PM EST
Source: Reuters
Importance Score:
8
Price at Filing: $28.80
Real-time Price: $27.89 info
Change: -$0.9078 (-3%) info
Market Cap: $4.521B info
ADPT
Sep 17, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $27.98
Real-time Price: $27.89 info
Change: -$0.0879 (-0.31%) info
Market Cap: $4.521B info
ADPT
Aug 19, 2026, 8:15 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $25.80
Real-time Price: $27.89 info
Change: +$2.09 (+8%) info
Market Cap: $4.521B info
ADPT
Aug 04, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $24.66
Real-time Price: $27.89 info
Change: +$3.23 (+13%) info
Market Cap: $4.521B info
ADPT
Jul 29, 2026, 4:23 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $22.15
Real-time Price: $27.89 info
Change: +$5.74 (+26%) info
Market Cap: $4.521B info
ADPT
Jul 29, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $22.59
Real-time Price: $27.89 info
Change: +$5.30 (+23%) info
Market Cap: $4.521B info
ADPT
Jul 01, 2026, 4:35 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $22.76
Real-time Price: $27.89 info
Change: +$5.13 (+23%) info
Market Cap: $4.521B info
ADPT
Jun 22, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $17.37
Real-time Price: $27.89 info
Change: +$10.52 (+61%) info
Market Cap: $4.521B info
ADPT
Jun 17, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $17.13
Real-time Price: $27.89 info
Change: +$10.76 (+63%) info
Market Cap: $4.521B info
ADPT
Jun 15, 2026, 4:50 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $16.50
Real-time Price: $27.89 info
Change: +$11.39 (+69%) info
Market Cap: $4.521B info
ADPT
Jun 15, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $15.97
Real-time Price: $27.89 info
Change: +$11.92 (+75%) info
Market Cap: $4.521B info
ADPT
Jun 15, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $15.90
Real-time Price: $27.89 info
Change: +$11.99 (+75%) info
Market Cap: $4.521B info
ADPT
May 29, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $15.19
Real-time Price: $27.89 info
Change: +$12.70 (+84%) info
Market Cap: $4.521B info
ADPT
May 05, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $15.70
Real-time Price: $27.89 info
Change: +$12.19 (+78%) info
Market Cap: $4.521B info
ADPT
May 05, 2026, 4:27 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $16.00
Real-time Price: $27.89 info
Change: +$11.89 (+74%) info
Market Cap: $4.521B info
ADPT
May 05, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.00
Real-time Price: $27.89 info
Change: +$12.89 (+86%) info
Market Cap: $4.521B info
ADPT
Apr 24, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $14.14
Real-time Price: $27.89 info
Change: +$13.75 (+97%) info
Market Cap: $4.521B info
ADPT
Mar 16, 2026, 8:40 PM EDT
Filing Type: 144
Importance Score:
9
Price at Filing: $13.32
Real-time Price: $27.89 info
Change: +$14.57 (+109%) info
Market Cap: $4.521B info
ADPT
Mar 16, 2026, 8:33 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $13.32
Real-time Price: $27.89 info
Change: +$14.57 (+109%) info
Market Cap: $4.521B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets